WEAV Stock Analysis: Weave Communications | NYSE
Health Information Services | NYSE, USA | Market Cap: 401m USD | 12M Return: -9% | US94724R1086 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.02M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 4.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Weave Communications, Inc. (NYSE: WEAV) is a software company that provides an AI-powered patient communications, engagement, and payments platform aimed at small and medium-sized healthcare businesses. Its product suite covers phone systems (including an AI receptionist, softphones, and call intelligence), two-way text messaging with auto-reply, online scheduling, digital forms, insurance eligibility and verification, reviews management, email marketing, team chat, and integrated payment processing. The company serves multi-location practices in dental, vision, veterinary, and medical verticals, offering a dedicated enterprise tier for larger groups such as dental service organizations. Weave was founded in 2008, is headquartered in Lehi, Utah, was previously named Recall Solutions, LLC, and went public in November 2021.
The company operates as a vertical SaaS provider within the application software sub-industry, selling a bundled communications and payments subscription to healthcare practices rather than selling standalone point products. This vertical focus on healthcare SMBs is a common go-to-market approach in the broader small-business software sector, where vendors typically generate recurring subscription revenue supplemented by transaction-based fees from payment processing and other usage-driven services.
- Payments attach rate accelerates revenue per location
- AI receptionist and automation tools drive product upsell
- Net dollar retention reflects SMB healthcare vertical demand health
| Net Income: -20.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.15 > 1.0 |
| NWC/Revenue: 8.04% < 20% (prev 8.20%; Δ -0.16% < -1%) |
| CFO/TA 0.08 > 3% & CFO 16.9m > Net Income -20.5m |
| Net Debt (-27.1m) to EBITDA (3.35m): -8.09 < 3 |
| Current Ratio: 1.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (79.6m) vs 12m ago 6.42% < -2% |
| Gross Margin: 72.34% > 18% (prev 71.85%; Δ 0.49% > 0.5%) |
| Asset Turnover: 124.9% > 50% (prev 108.1%; Δ 16.79% > 0%) |
| Interest Coverage Ratio: -11.99 > 6 (EBIT TTM -18.6m / Interest Expense TTM 1.55m) |
| A: 0.10 (Total Current Assets 104.7m - Total Current Liabilities 84.0m) / Total Assets 208.6m |
| B: -1.58 (Retained Earnings -329.1m / Total Assets 208.6m) |
| C: -0.09 (EBIT TTM -18.6m / Avg Total Assets 206.5m) |
| D: 0.69 (Book Value of Equity 85.0m / Total Liabilities 123.6m) |
| Altman-Z'' = -4.38 = D |
| DSRI: 1.12 (Receivables 4.44m/3.39m, Revenue 257.8m/220.8m) |
| GMI: 0.99 (GM 71.85% / 72.34%) |
| AQI: 0.99 (AQ_t 0.24 / AQ_t-1 0.24) |
| SGI: 1.17 (Revenue 257.8m / 220.8m) |
| TATA: -0.18 (NI -20.5m - CFO 16.9m) / TA 208.6m) |
| Beneish M = -2.83 (Cap -4..+1) = A |
As of August 19, 2026, the stock is trading at USD 7.28 with a total of 49,372,084 shares traded. Over the past week, the price has changed by +44.73%, over one month by +1.82%, over three months by +33.82% and over the past year by -9.00%.
Current recommended Stop Loss: 6.60 (which is 9.3% or 1.7 ATR below the current price).
Weave Communications has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy WEAV.
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 8 | 9.9% |
P/S = 1.5548
P/B = 5.0182
Revenue TTM = 257.8m USD
EBIT TTM = -18.6m USD
EBITDA TTM = 3.35m USD
Long Term Debt = 39.4m USD (estimated: total debt 51.4m - short term 11.9m)
Short Term Debt = 11.9m USD (from shortTermDebt, last quarter)
Debt = 51.4m USD (from shortLongTermDebtTotal, last quarter) (leases 51.4m already included)
Net Debt = -27.1m USD (calculated: Debt 51.4m - CCE 78.5m)
Enterprise Value = 373.7m USD (400.8m + Debt 51.4m - CCE 78.5m)
Interest Coverage Ratio = -11.99 (Ebit TTM -18.6m / Interest Expense TTM 1.55m)
EV/FCF = 26.14x (Enterprise Value 373.7m / FCF TTM 14.3m)
FCF Yield = 3.83% (FCF TTM 14.3m / Enterprise Value 373.7m)
FCF Margin = 5.55% (FCF TTM 14.3m / Revenue TTM 257.8m)
Net Margin = -7.97% (Net Income TTM -20.5m / Revenue TTM 257.8m)
Gross Margin = 72.34% ((Revenue TTM 257.8m - Cost of Revenue TTM 71.3m) / Revenue TTM)
Gross Margin QoQ = 72.03% (prev 72.38%)
Tobins Q-Ratio = 1.79 (Enterprise Value 373.7m / Total Assets 208.6m)
Interest Expense / Debt = 3.03% (Interest Expense 1.55m / Debt 51.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -14.7m (EBIT -18.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.25 (Total Current Assets 104.7m / Total Current Liabilities 84.0m)
Debt / Equity = 0.60 (Debt 51.4m / totalStockholderEquity, last quarter 85.0m)
Debt / EBITDA = -8.09 (Net Debt -27.1m / EBITDA 3.35m)
Debt / FCF = -1.89 (Net Debt -27.1m / FCF TTM 14.3m)
Total Stockholder Equity = 82.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.95% (Net Income -20.5m / Total Assets 208.6m)
RoE = -24.96% (Net Income TTM -20.5m / Total Stockholder Equity 82.3m)
RoCE = -15.31% (EBIT -18.6m / Capital Employed (Equity 82.3m + L.T.Debt 39.4m))
RoIC = -11.91% (negative operating profit) (NOPAT -14.7m / Invested Capital 123.7m)
WACC = 9.89% (E(400.8m)/V(452.2m) * Re(10.85%) + D(51.4m)/V(452.2m) * Rd(3.03%) * (1-Tc(0.21)))
Discount Rate = 10.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.05 | Cagr: 5.59%
[DCF] Terminal Value 70.21% ; FCFF base≈14.3m ; Y1≈14.3m ; Y5≈15.2m
[DCF] Fair Price = 2.68 (EV 186.9m - Net Debt -27.1m = Equity 214.0m / Shares 80.0m; r=9.89% [WACC]; 5y FCF grow -0.14% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.21 | # QB: 0
Revenue Correlation: 99.90 | Revenue CAGR: 18.23% | SUE: -0.61 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.04 | Chg30d=-5.56% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=0.17 | Chg30d=+1.49% | Revisions=+50% | GrowthEPS=+112.5% | GrowthRev=+14.7%
EPS next Year (2027-12-31): EPS=0.25 | Chg30d=+5.32% | Revisions=+50% | GrowthEPS=+45.6% | GrowthRev=+13.6%
[Analyst] Revisions Ratio: +70% (up=7, down=0)